Faecal calprotectin and gut microbiota do not predict enteropathy in very preterm infants

Florence Campeotto, Caroline Elie, Clotilde Rousseau, Agnès Giuseppi, Taymme Hachem, Ponny Gobalakichenane, Mathilde Le Touzey, Marie de Stefano, Marie-José Butel, Nathalie Kapel, Florence Campeotto, Caroline Elie, Clotilde Rousseau, Agnès Giuseppi, Taymme Hachem, Ponny Gobalakichenane, Mathilde Le Touzey, Marie de Stefano, Marie-José Butel, Nathalie Kapel

Abstract

Aim: Very preterm birth is associated with a high risk of enteropathies. Diagnosis is challenging, especially in mild forms, leading to unnecessary periods of cessation of enteral feeding. This study aimed at establishing a prognosis score of enteropathy combining clinical parameters and faecal calprotectin concentration.

Methods: This prospective multicentric study included preterm neonates born at a gestational age of 33 weeks or less. Stools were collected weekly until hospital discharge, and daily in case of digestive events for calprotectin measurement (ELISA and immunochromatography) and microbiota analyses (16S rRNA gene sequencing).

Results: Among the 121 neonates included, 21 experienced at least one episode of enteropathy, mainly mild forms. By ELISA testing, median faecal calprotectin was 88 (8-798) µg/g faeces. No statistically significant association was found between the outset of enteropathy and maternal and neonatal characteristics, and calprotectin levels. The agreement between ELISA and immunochromatography assay was moderate (intra-class correlation coefficient 0.58, 95%CI [0.47-0.66]). Comparison of species diversity and relative bacterial abundance profiles between infants with or without enteropathy revealed no specific alterations associated with enteropathy.

Conclusion: The study failed to propose a prognostic score of enteropathy, probably due the large inter- and intra-individual variability of faecal calprotectin in very preterm neonates.

Trial registration: ClinicalTrials.gov NCT02010268.

Keywords: enteropathy; faecal calprotectin; gut microbiota; necrotising enterocolitis; preterm neonates.

Conflict of interest statement

None declared.

© 2020 The Authors. Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica.

Figures

FIGURE 1
FIGURE 1
Individual evolution of faecal calprotectin in the 21 neonates suffering from enteropathy event(s). Events are identified by the first day (D) of enteral feeding discontinuation (vertical dotted line): 18 patients with mild enteropathy (suspected NEC, Bell stage Ia and Bell stage Ib), and 5 with severe enteropathy (definite NEC, patients 80 (D71), 86, 120 and 121: Bell stage IIA; patient 104: Bell stage IIb). Blue line: faecal calprotectin (FC) by ELISA; pink line: FC by immunochromatographic (IC) assay
FIGURE 2
FIGURE 2
Microbiota profiles in neonates suffering from enteropathy and matching controls. A, Relative abundance of sequence reads at the phylum level assigned to different bacterial taxa in each neonate. B, Bacterial alpha‐diversity using the Chao‐1, Shannon and Inverse Simpson Diversity Indexes in control and neonates suffering from enteropathy. C, Beta‐diversity was analysed using multidimensional scaling (MDS) plot of samples according to disease status (enteropathy vs control) on the weighted‐UniFrac distance metrics

References

    1. Battersby C, Santhalingam T, Costeloe K, Modi N. Incidence of neonatal necrotising enterocolitis in high‐income countries: a systematic review. Arch Dis Child Fetal Neonatal Ed. 2018;103:F182‐F189.
    1. Kliegman RM, Walsh MC. Neonatal necrotizing enterocolitis: pathogenesis, classification, and spectrum of illness. Curr Probl Pediatr. 1987;17:219‐288.
    1. Campeotto F, Kalach N, Lapillonne A, Butel MJ, Dupont C, Kapel N. Time course of faecal calprotectin in preterm newborns during the first month of life. Acta Paediatr. 2007;96:1531‐1533.
    1. Rich BS, Dolgin SE. Necrotizing Enterocolitis. Pediatr Rev. 2017;38:552‐559.
    1. Gephart SM, Gordon PV, Penn AH, et al. Changing the paradigm of defining, detecting, and diagnosing NEC: Perspectives on Bell's stages and biomarkers for NEC. Semin Pediatr Surg. 2018;27:3‐10.
    1. Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet. 2000;356:1783‐1784.
    1. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta‐analysis. BMJ. 2010;341:c3369.
    1. Heida A, Van de Vijver E, van Ravenzwaaij D, et al. Predicting inflammatory bowel disease in children with abdominal pain and diarrhoea: calgranulin‐C versus calprotectin stool tests. Arch Dis Child. 2018;103:565‐571.
    1. Kapel N, Campeotto F, Kalach N, Baldassare M, Butel MJ, Dupont C. Faecal calprotectin in term and preterm neonates. J Pediatr Gastroenterol Nutr. 2010;51:542‐547.
    1. Pergialiotis V, Konstantopoulos P, Karampetsou N, et al. Calprotectin levels in necrotizing enterocolitis: a systematic review of the literature. Inflamm Res. 2016;65:847‐852.
    1. Campeotto F, Baldassarre M, Butel MJ, et al. Fecal calprotectin: cutoff values for identifying intestinal distress in preterm infants. J Pediatr Gastroenterol Nutr. 2009;48:507‐510.
    1. Bekkali N, Hamers SL, Reitsma JB, Van Toledo L, Benninga MA. Infant stool form scale: development and results. J Pediatr. 2009;154(521–6):e1.
    1. Ton H, Brandsnes DS, Holtlund J, et al. Improved assay for fecal calprotectin. Clin Chim Acta. 2000;292:41‐54.
    1. Rousseau C, Levenez F, Fouqueray C, Dore J, Collignon A, Lepage P Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition. J Clin Microbiol. 2011;49:858‐865.
    1. Escudie F, Auer L, Bernard M, et al. FROGS: Find, Rapidly, OTUs with Galaxy Solution. Bioinformatics (Oxford, England). 2018;34:1287‐1294.
    1. Federhen S. The NCBI Taxonomy database. Nucleic Acids Res. 2012;40:D136‐D143.
    1. Cole JR, Wang Q, Fish JA, et al. Ribosomal Database Project: data and tools for high throughput rRNA analysis. Nucleic Acids Res. 2014;42:D633‐D642.
    1. Yang Q, Smith PB, Goldberg RN, Cotten CM. Dynamic change of fecal calprotectin in very low birth weight infants during the first month of life. Neonatology. 2008;94:267‐271.
    1. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307‐310.
    1. MacQueen BC, Christensen RD, Yost CC, et al. Reference intervals for stool calprotectin in preterm neonates and their utility for the diagnosis of necrotizing enterocolitis. J Perinatol. 2018;38:1379‐1385.
    1. Ho TTB, Groer MW, Kane B, et al. Enteric dysbiosis and fecal calprotectin expression in premature infants. Pediatr Res. 2019;85:361‐368.
    1. van Zoonen A, Hulzebos CV, Muller Kobold AC, Kooi EMW, Bos AF, Hulscher JBF. Serial fecal calprotectin in the prediction of necrotizing enterocolitis in preterm neonates. J Pediatr Surg. 2019;54:455‐459.
    1. Nakayuenyongsuk W, Christofferson M, Stevenson DK, Sylvester K, Lee HC, Park KT. Point‐of‐Care Fecal Calprotectin Monitoring in Preterm Infants at Risk for Necrotizing Enterocolitis. J Pediatr. 2018;196(98–103):e1.
    1. Yoon JM, Park JY, Ko KO, Lim JW, Cheon EJ, Kim HJ. Fecal calprotectin concentration in neonatal necrotizing enterocolitis. Korean J Pediatr. 2014;57:351‐356.
    1. Labaere D, Smismans A, Van Olmen A, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J. 2014;2:30‐37.
    1. Roze JC, Ancel PY, Lepage P, et al. Nutritional strategies and gut microbiota composition as risk factors for necrotizing enterocolitis in very‐preterm infants. Am J Clin Nutr. 2017;106:821‐830.
    1. Benahmed NA, Manene D, Barbot‐Trystram L, Kapel N. Evaluation of Calfast(R) immunochromatographic quantitative assay for the measurement of calprotectin in faeces. Clin Chem Lab Med. 2014;52:e143‐e145.
    1. Baldassarre ME, Di Mauro A, Capozza M, et al. Dysbiosis and prematurity: is there a role for probiotics? Nutrients. 2019;11(6):1273.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren